Want to see CADL full AI Analyst Report?
CADL Stock Chart & Stats
$9.56
$0.40(4.18%)
At close: 4:00 PM EDT
$9.56
$0.40(4.18%)
Day’s Range― - ―
52-Week Range$4.35 - $11.36
Previous Close$10.1
Volume1.27M
Average Volume (3M)1.77M
Market Cap
$769.34M
Enterprise Value$160.01
Total Cash (Recent Filing)$194.83M
Total Debt (Recent Filing)$1.80M
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Aug 19, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.98
Shares Outstanding73,270,240
10 Day Avg. Volume1,254,266
30 Day Avg. Volume1,766,682
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)5.76
Price to Sales (P/S)0.00
P/FCF Ratio-7.69
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$20.17Price Target Upside110.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.93
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Strengthened Equity BaseA materially stronger balance sheet with very low leverage provides durable financial flexibility to fund clinical programs and pursue partnerships without immediate refinancing pressure. This reduces short-term solvency risk and supports continuing R&D execution across 2–6 months while trials progress.
Positive Phase 3 Clinical Data MomentumAccumulating randomized Phase 3 follow-up data strengthens the clinical efficacy narrative for the lead program, improving the company's prospects for regulatory engagement, strategic partnerships or commercialization planning. Durable clinical progress raises the long-term value of the pipeline beyond short-term noise.
Governance Continuity And Retained Financial LeadershipRe-election of experienced directors, retention of an independent auditor and a formalized CFO agreement reduce execution risk by preserving leadership continuity and financial oversight. Stable governance and aligned executive incentives support consistent strategy execution over the medium term.
Bears Say
Pre-revenue Business ModelBeing pre-revenue means the company lacks recurring commercial cash inflows and remains dependent on external financing or partnerships to fund operations. This structural positioning increases execution and commercialization risk and makes long-term sustainability contingent on successful clinical outcomes or deal activity.
Significant And Persistent Cash BurnConsistent negative operating and free cash flow at scale consumes equity and shortens runway absent new capital or deals. Ongoing cash burn heightens dilution risk and may force program delays or restructurings, making sustained R&D progress dependent on reliable future financing or strategic partnerships.
Large Net Losses And Negative Returns On EquityDeep, persistent net losses and highly negative ROE indicate current capital deployment is destroying shareholder value. Over the medium term this raises pressure for shifts in strategy, potential asset prioritization or additional financing, all of which can materially affect long-term shareholder outcomes.
Candel Therapeutics News
CADL FAQ
What was Candel Therapeutics, Inc.’s price range in the past 12 months?
Candel Therapeutics, Inc. lowest stock price was $4.35 and its highest was $11.36 in the past 12 months.
What is Candel Therapeutics, Inc.’s market cap?
Candel Therapeutics, Inc.’s market cap is $769.34M.
When is Candel Therapeutics, Inc.’s upcoming earnings report date?
Candel Therapeutics, Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 6 days.
How were Candel Therapeutics, Inc.’s earnings last quarter?
Candel Therapeutics, Inc. released its earnings results on May 14, 2026. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.296 by $0.156.
Is Candel Therapeutics, Inc. overvalued?
According to Wall Street analysts Candel Therapeutics, Inc.’s price is currently Undervalued.
Does Candel Therapeutics, Inc. pay dividends?
Candel Therapeutics, Inc. does not currently pay dividends.
What is Candel Therapeutics, Inc.’s EPS estimate?
Candel Therapeutics, Inc.’s EPS estimate is -0.23.
How many shares outstanding does Candel Therapeutics, Inc. have?
Candel Therapeutics, Inc. has 73,270,240 shares outstanding.
What happened to Candel Therapeutics, Inc.’s price movement after its last earnings report?
Candel Therapeutics, Inc. reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.296. Following the earnings report the stock price went down -0.336%.
Which hedge fund is a major shareholder of Candel Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CADL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Candel Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.17 (110.95% Upside)
$20.17 (110.95% Upside)
Blogger Sentiment
Bullish
CADL Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 156.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.3%
Last 30 Days ▲ 6.3%
Last 30 Days ▲ 6.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.88%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
110.54%
Trailing 12-Months
Company Description
Candel Therapeutics, Inc.
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
CADL Stock 12 Month Forecast
Average Price Target
$20.17
▲(110.95% Upside)
Technical Analysis
CytomX Therapeutics
―
Replimune Group
―
Immatics
―
Lyell Immunopharma
―
Artiva Biotherapeutics, Inc.
―
Ownership Overview
9.47% Insiders
17.35% Mutual Funds
2.49% Other Institutional Investors
58.18% Public Companies and
Individual Investors